SEC Form 4 · accession 0001209191-18-016827
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret G McGlynn
Director
Period of report
Mar 2, 2018
Accepted (ET)
Mar 5, 2018 · 6:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2018 | M | 10,000 | $81.54 | A | 16,312 | D | |
| Common Stock | Mar 2, 2018 | S | 10,000 | $170.00 | D | 6,312 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $81.54 | Mar 2, 2018 | M | 10,000 | D | — | May 31, 2023 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- F2Fully vested.